Related references
Note: Only part of the references are listed.PDE3, but not PDE4, reduces β1- and β2-adrenoceptor-mediated inotropic and lusitropic effects in failing ventricle from metoprolol-treated patients
Peter Molenaar et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Cyclic Adenosine Monophosphate Phosphodiesterase Type 4 Protects Against Atrial Arrhythmias
Cristina E. Molina et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Profiling of cAMP and cGMP phosphodiesterases in isolated ventricular cardiomyocytes from human hearts: Comparison with rat and guinea pig
W. B. Johnson et al.
LIFE SCIENCES (2012)
Meta-analysis identifies six new susceptibility loci for atrial fibrillation
Patrick T. Ellinor et al.
NATURE GENETICS (2012)
Conserved expression and functions of PDE4 in rodent and human heart
Wito Richter et al.
BASIC RESEARCH IN CARDIOLOGY (2011)
Phosphodiesterase 4B in the cardiac L-type Ca2+ channel complex regulates Ca2+ current and protects against ventricular arrhythmias in mice
Jerome Leroy et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Constitutive phosphodiesterase activity restricts spontaneous beating rate of cardiac pacemaker cells by suppressing local Ca2+ releases
Tatiana M. Vinogradova et al.
CIRCULATION RESEARCH (2008)
Cilostamide potentiates more the positive inotropic effects of (-)-adrenaline through β2-adrenoceptors than the effects of (-)-noradrenaline through β1-adrenoceptors in human atrial myocardium
T. Christ et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2006)
Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias
SE Lehnart et al.
CELL (2005)
Roflumilast -: an oral anti-inflammatory treatment for chronic obstructive pulmonary disease:: a randomised controlled trial
KF Rabe et al.
LANCET (2005)
What is the role of β-adrenergic signaling in heart failure?
MJ Lohse et al.
CIRCULATION RESEARCH (2003)
Share Paper
